1. Accelerometer-measured physical activity in patients with heart failure and reduced ejection fraction: Determinants and relationship with patient-reported health status.
- Author
-
Fuchs Andersen C, Omar M, Larsen JH, Kistorp C, Tuxen C, Gustafsson F, Køber L, Poulsen MK, Brønd JC, Møller JE, Schou M, and Jensen J
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Patient Reported Outcome Measures, Anemia physiopathology, Anemia epidemiology, Heart Failure physiopathology, Stroke Volume physiology, Accelerometry, Exercise physiology, Health Status
- Abstract
Background: Accelerometer-measured physical activity is an increasingly used endpoint in heart failure (HF) trials. We investigated the determinants of accelerometer-measured physical activity and the relationship with patient-reported health status., Methods: Post-hoc analysis of the Empire HF trial, including outpatients with HF with reduced ejection fraction (HFrEF). Physical activity was quantified as average accelerometer counts per minute (CPM) with higher values representing higher activity. We investigated associations between activity level and clinical variables, including age, sex, and body mass index, as well as patient-reported health status assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)., Results: Complete data were available in 180 (95%) patients (86% male, mean age 65 year). Baseline median physical activity level was 1,318 CPM (Q1-Q3 1,111-1,585). Age and anemia were independently associated with activity level (β-coefficients: -10 CPM per year age increase [95% CI -16 to -5.1], P = .00015, and -126 CPM for anemia [95% CI -9.1 to -244], P = .035). Significant independent associations were observed between activity level and all KCCQ summary scores (β-coefficient point estimates of 3.7, 4.6, and 4.9 CPM, all P < .02). For 12-week changes in KCCQ-summary scores, only the KCCQ-CSS was associated with activity level; mean increase of 17.5 CPM [95% CI 1.5 to 34.0], P = 0.032, per 5-point increase in KCCQ-CSS. Associations were not modified by treatment allocation (interaction P-values > .05)., Conclusions: In patients with HFrEF, older age and anemia were independently associated with lower activity. Moreover, physical activity only weakly increased with better health status, suggesting that changes in physical activity reflect improvements in patients' health status to a limited degree. This highlights the need to better understand the endpoint with regards to all other health parameters to ease interpretation in future HF trials., Competing Interests: Conflict of Interest C.F.A. reports grant from the Danish Heart Foundation, Toyota-Fonden Denmark, Arvid Nilsson's Foundation, Aase & Ejnar Danielsen's Foundation, Fru Asta Florida Bolding's Memorial Grant, KV Foundation and The Research and Innovation Foundation of the Department of Cardiology (FUHAS, formerly FUKAP), Herlev and Gentofte University Hospital, Herlev, Denmark; personal fees from AstraZeneca, all outside the submitted work. J.J. reports grants from The Danish Heart Foundation, Denmark, and The CARDIOHGH at the Department of Cardiology, Herlev and Gentofte University Hospital, Denmark, during the conduct of the submitted work; personal fees from scientific advisory board from AstraZeneca and Boehringer Ingelheim, outside the submitted work; grants from The Research Council at Herlev and Gentofte University Hospital, Denmark, grants from The CARDIOHGH (formerly FUHAS), Herlev and Gentofte University Hospital, Denmark, and grants from The A.P. Møller Foundation for the Advancement of Medical Science, Denmark [as sub-investigator of the Empire HF trial]. M.A.O reports grants from the Danish Heart Foundation, grants from The Steno Diabetes Center Odense, Denmark and grants from A.P. Møller Foundation during the conduct of the study. C.T. reports speaker fees from Orion Pharma, personal fees for advisory board participation from Boehringer Ingelheim and Bayer A/S, all outside the submitted work. F.G. reports speaker fees from Orion Pharma, Vifor Pharma and Novartis, and personal fees for advisory board participation from Abbott, Pfizer, Astra-Zeneca, Ionis, Alnylam and Bayer, all outside the submitted work. J.E.M. reports speaker fees from Novartis, Boehringer Ingelheim, Abiomed, Orion and Abbott, advisory board from Orion and Boehringer Ingelheim, and research grant Abiomed and Roche, all outside submitted work. M.S. reports grants from The Capital Region of Denmark, grants from The Danish Heart Foundation, during the conduct of the study; personal fees and nonfinancial support from AstraZeneca, personal fees from Novo Nordisk and Boehringer Ingelheim, outside the submitted work., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF